Phase 4 N=60 Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea
Sleep Apnea, Obstructive
Primary: Cross Sectional Area of the Pharyngeal Airway — 239.9; 178.5; 201.6; 235.4 mm^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=850 REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
HIV Infection
Primary: Cumulative Probability of Death or Unknown Vital Status by Week 24 — 5.2; 5.2 Cumulative probability per 100 persons — p=0.97
Phase 4 N=10 Anti-platelet Effects of Colchicine in Healthy Volunteers
Healthy
Primary: Monocyte Platelet Aggregate: Baseline — 27.8 percentage of monocyte-platelet aggregat
Phase 4 N=31 Sugammadex ED90 Dose in the Obese Patients
Incomplete Reversal of Neuromuscular Block
Primary: Sugammadex ED90 — 2.40 mg/kg
Phase 4 N=197 A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Envelope Antigen Seroconversion at Week 48 — 14.89; 6.12 Percentage of participants
Phase 4 N=90 A Trial Of Oral Chloral Hydrate Versus Intranasal Dexmedetomidine For Sedated Abr Exams
Sedation
Primary: Time to Complete Study — 85.5; 110 Minutes
Phase 4 N=8 Short Bowel Syndrome and Teduglutide Versus Placebo
Short Bowel Syndrome
Primary: Gastric Emptying Half-Time (T1/2) — 113; 106 minutes — p=0.74
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
Phase 4 N=80 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline in Global Ocular Staining Score in the Study Eye — 5.2; 5.2; -1.5; -1.6 Scores on a Scale
Phase 4 N=38 Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Impetigo · Folliculitis · Secondarily Infected Eczema
Primary: Number of Participants Whose Wound Cultures Were Positive for MRSA and Who Were Determined to be a Clinical Success at the Follow-up Visit — 5 participants
Phase 4 N=243 Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)
Pneumococcal Infection
Primary: Change From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Revaccination — 2.72; 2.27; 2.40 Geometric Mean Fold Rise — p=<0.001
Phase 4 N=204 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder
Vitamin D Deficiency
Primary: The Blood Levels of Calcium at the 24th Month of Following up. — 2.31; 2.33 mmol/L — p=0.117
Phase 4 N=307 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
Retinal Vein Occlusion · Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) — 56.6; 59.2; 7.9; 16.9 letters
Phase 4 N=100 Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery
Pain
Primary: Efficacy of Pain Relief (Pain Intensity at Rest) — 30; 32 units on a scale (in mm)
Phase 4 N=1,034 A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough FEV1 on Day 85 — 0.123; 0.099 Liter — p=0.100